Paclitaxel micelle formulation - Nippon Kayaku/NanoCarrier

Drug Profile

Paclitaxel micelle formulation - Nippon Kayaku/NanoCarrier

Alternative Names: Macromolecular micelle paclitaxel; NK 105; Polymeric micelle paclitaxel

Latest Information Update: 31 May 2016

Price : $50

At a glance

  • Originator NanoCarrier
  • Developer Nippon Kayaku
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Gastric cancer
  • Phase I Solid tumours

Most Recent Events

  • 18 May 2016 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Japan (IV) (JapicCTI163257)
  • 15 Mar 2016 Biomarkers information updated
  • 17 Jul 2012 Phase-III clinical trials in Breast cancer in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top